Company Overview and News
QUÉBEC, 01 mai 2018 (GLOBE NEWSWIRE) -- SOCIÉTÉ D’EXPLORATION MINIÈRE VIOR INC. (« Vior ») (TSX CROISSANCE:VIO) (FRANCFORT:VL51) a le plaisir d'annoncer la signature d'une deuxième entente d'option et de coentreprise avec Iluka Exploration (Canada) Ltd (« Iluka »), une filiale à part entière de Iluka Resources Limited (ASX:ILU), un des plus grands producteurs de rutile et de rutile synthétique à haute teneur en dioxyde de titane.
QUEBEC CITY, May 01, 2018 (GLOBE NEWSWIRE) -- SOCIÉTÉ D’EXPLORATION MINIÈRE VIOR INC. ("Vior"), (TSX-Venture:VIO) (FRANKFURT:VL51) – is pleased to announce that it has entered into a second option and joint venture agreement with Iluka Exploration (Canada) Ltd. ("Iluka"), a wholly-owned subsidiary of Iluka Resources Limited (ASX:ILU), one of the largest producers of the high-grade titanium dioxide products of rutile and synthetic rutile.
Western Australia’s Department of Mines, Industry Regulation and Safety is investigating the death of a worker who was stung by a bee at Iluka Resources’ Cataby mineral sands project earlier this year.
THE WA Department of Mines, Industry Regulation and Safety is investigating the death of a 34-year-old worker who was stung by a bee at Iluka Resources’ Cataby project north of Perth two months ago.
Iluka Resources has been served with a class action, with a group of shareholders alleging the mineral sands miner misled the market six years ago.
Broken Hill Prospecting Ltd (ASX:BPL) remains undervalued despite strong recent news flow from its flagship cobalt joint venture near Broken Hill and its position as the largest mineral sands tenement holder in the prolific Murray Basin.
After years of cost cutting their way to earnings growth, Australia's listed corporate sector is finally showing signs of getting on board with the global economic recovery.
At its meeting today, the Board decided to leave the cash rate unchanged at 1.50 per cent - https://t.co/ahK2GWuwLx
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) continues to climb higher just after midday, sitting near its intra-day highs.
Image Resources NL (ASX:IMA) is finalising the award of a contract for constructing the site entry intersection for its zircon-rich Boonanarring Mineral Sands Project in the North Perth Basin.
SIMPEC secured its first contract for construction work at Iluka Resources’ Cataby mineral sands development in Western Australia last November.
WestStar Industrial Ltd (ASX:WSI) has completed the procurement phase of the mechanical, electrical and communications contract at Iluka Resources’(ASX:ILU) Cataby Project.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
An investor looks at a board displaying stock prices at the Australian Securities Exchange (ASX) in Sydney October 14, 2016. — Reuters picSYDNEY, Jan 31 — Australia’s benchmark index is among the developed world’s worst performers so far this year, yet investors are expected to reap rewards in other ways.
Australian shares climbed solidly on Monday to start the week on an upbeat note, with Commonwealth Bank investors taking the news of a new CEO in their stride.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...